Aptn KRX:270520KOSDAQ
앱튼 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days1
Articles tracked15since Sep 11
In Q2 2026, Aptn reported revenue of ₩3.4bn, up 18.8% year on year, and an operating loss of ₩1.3bn. Aptn (앱튼) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 1 article.
Filing signals Supply contract M&A / stake deal 4 quarters of losses Screener
Aptn quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩3.4bn | +18.8% | −₩1.3bn margin −39.4% | −₩3.9bn |
| Q1 2026 | ₩4.5bn | -30.9% | −₩1.8bn margin −39.1% | −₩13.2bn |
| Q4 2025 derived | ₩2.3bn | -39.4% | −₩3.6bn margin −156.5% | −₩7.6bn |
| Q3 2025 | ₩5.2bn | +17.4% | −₩1.0bn margin −20.1% | −₩4.3bn |
| Q2 2025 | ₩2.8bn | -46.2% | −₩4.0bn margin −140.7% | −₩22.2bn |
| Q1 2025 | ₩6.6bn | +34.9% | −₩2.5bn margin −38.0% | ₩9.4bn |
| Q4 2024 derived | ₩3.8bn | -24.7% | −₩7.4bn margin −192.0% | −₩12.4bn |
| Q3 2024 | ₩4.4bn | +47.3% | −₩1.9bn margin −43.2% | −₩2.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aptn top stories 2 weeks, by number of outlets
- 1
- 2
Latest Aptn news Korean headlines
-
에이프로젠 자회사 앱튼, 혈액암 신약 GPC-100 글로벌 임상 3상 추진"
1 more on this story · 1 outlets
- 앱튼, 혈액암 신약 'GPC-100' 글로벌 3상 착수...인허가 절차 돌입글로벌경제신문 · Sep 17 11:53
-
앱튼, GPC-100 글로벌 3상 준비 본격화…에이프로젠 임상팀 가동
5 more on this story · 5 outlets
- 앱튼, 'GPC-100' 글로벌 임상 3상 본격 착수…에이프로젠 임상팀 구축머니투데이 · Sep 17 10:53
- 앱튼, 'GPC-100' 글로벌 임상 3상 추진…에이프로젠 임상팀 가동데일리한국 · Sep 17 11:23
- 앱튼, GPC-100 글로벌 임상 3상 착수∙에이프로젠 임상팀 전격 가동바이오타임즈 · Sep 17 11:31
- 앱튼, 'GPC-100' 글로벌 3상 채비…에이프로젠 임상팀 투입파이낸셜뉴스 · Sep 17 11:34
- 앱튼, ‘GPC-100’ 글로벌 3상 준비 본격화…FDA 협의 추진메디컬투데이 · Sep 17 13:14